Mumbai, Nov 18: Pharma major JB Chemicals and Pharmaceuticals Ltd (JBCPL) has launched two new therapeutic products, Cefjoy and Zudo, targeting anti-bacterial and nutraceutical segments in India. Cefjoy (Cefpodoxime Proxetil) is a third generation orally-administered Cephalosporin for treatment of a wide range of infections in adult and paediatric patients, JBCPL said in a release here on Monday.
The drug is a combination of Cefpodoxime and Lactobacillus, and is available in tablets and dry syrup dosage forms, it said.
JBCPL estimates the total market size of the product to be around Rs 155 crore, with a 51 percent growth in the country, it said.
Zudo is a soft gelatin capsule supplement containing multi-vitamins, multi-minerals, anti-oxidants and fatty acids to improve heart, bone, skin and neurological health, it said, adding market for the product is estimated to be at Rs 312 crore with a 11 percent growth.
Bureau Report